1. |
Cai H, Song LW. Clinical observation on the treatment of oral submucosa fibrosis with Glycyrrhiza glabra combined with Si Miao Yong An Tang plusreduction. Zhong Hua Zhong Yi Yao Xue Kang 2016; 34: 1486-8.
|
2. |
Jian XC, Gao X. Etiology pathogenesis diagnosis and treatment of oral submucosal fibrous lesions. Kou Qiang Ji Bing Fang Zhi 2021; 29: 217-25.
|
3. |
Peng Q, Li HY, Chen J, et al. Oral submucous fibrosis in Asian countries. J Oral Pathol Med 2020; 49: 294-304.
DOI
PMID
|
4. |
Arakeri G, Patil SG, Aljabab AS, et al. Oral submucous fibrosis: an update on pathophysiology of malignant transformation. J Oral Pathol Med 2017; 46: 413-7.
DOI
PMID
|
5. |
Shih YH, Wang TH, Shieh TM, et al. Oral submucous fibrosis: a review on etiopathogenesis diagnosis and therapy. Int J Mol Sci 2019; 20: 2940.
|
6. |
Chowdhury P, Nagamalini BR, Singh J, et al. Expressionof β-catenin in oral leukoplakia and oral submucous fibrosis: an immunohistochemical study. J Oral Maxillofac Pathol 2021; 25: 124-30.
|
7. |
Katase N, Lefeuvre M, Tsujigiwa H, et al. Knockdown of Dkk-3 decreasescancer cell migration and invasion independently of the Wnt pathways in oral squamous cell carcinoma-derived cells. Oncol Rep 2013; 29: 1349-55.
DOI
PMID
|
8. |
Zhang L, Tan J, Liu YP, et al. Effects of curcumin extract on TGF-β_1 IL-1 and Bcl-2 in OSF model rats and related mechanisms. Yi Nan Bing Za Zhi 2021; 20: 1152-6.
|
9. |
Adhikari S, Rimal J, Maharjan IK, et al. Efficacy of curcumin in combination with intralesional dexamethasone with hyaluronidase in the treatment of oral submucous fibrosis: a randomized controlled trial. Asian Pac J Cancer Prev 2022; 23: 3125-32.
|
10. |
Muller S, Tilakaratne WM. Update from the 5th edition of the world health organization classification of head and neck tumors: tumours of the oral cavity and mobile tongue. Head Neck Pathol 2022; 16: 54-62.
DOI
PMID
|
11. |
Yang B, Fu MF, Tang ZG. Construction of a rat oral submucosal fibrosismodel by betaine and mechanical stimulation. Hua Xi Kou Qiang Yi Xue Za Zhi 2019; 37: 260-4.
|
12. |
Shetty SS, Sharma M, Fonseca FP, et al. Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma. Jpn Dent Sci Rev 2020; 56: 97-108.
|
13. |
He Y, Jianng X. The role of epithelial-mesenchymal transition in oralsquamous cell carcinoma and oral submucous fibrosis. Clin Chim Acta 2007; 383: 51-6.
|
14. |
Ge WS, Wang YJ, Wu JX, et al. β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation. Mol Med Rep 2014; 9: 2145-51.
|
15. |
Bai Y, Sha J, Kanno T. The role of carcinogenesis-related biomarkers in the wnt pathway and their effects on Epithelial-Mesenchymal Transition (EMT) in oral squamous cell carcinoma. Cancers (Basel) 2020; 12: 555.
|
16. |
Ji L, Lu B, Zamponi R, et al. USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin. Nat Commun 2019; 10: 4184.
DOI
PMID
|
17. |
Li YC, Tan J, Chen A, et al. Effect of Dan Xuan Kou Kang on TGFβ expression in rats with oral submucosa fibrosis. Xin Zhong Yi 2006; 38: 89-91.
|
18. |
Tan J, Chen A. Clinical observation on the treatment of oral submucosal fibrosis with blood activation and fibrillation formula. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2001; 8: 71-2.
|
19. |
Yu Y. Clinical observation on the treatment of oral lichen planus with detoxifying and stasis-removing herbs combined with tretinoin oral ointment. Zhong Guo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu 2021; 19: 136-7.
|